Mysorekar: Microbiome in placenta took time to be accepted; first work in 2012. https://t.co/onRzjMv0qU #AMP2016
8:29am November 11th 2016 via Twitter Web Client
Mysorekar: What makes us what we are? Genome, epigenome, and microbiome ('that can be changed'). 100T cells, co-evolved w/genome #AMP2016
8:25am November 11th 2016 via Twitter Web Client
Mysorekar: Not surprising that disorders are manifold - from infertility, preeclampsia, miscarriage, preterm birth #AMP2016
8:23am November 11th 2016 via Twitter Web Client
Mysorekar: First 9 mos have enormous impact on the rest of a life: placenta serves as a lung, CV, immune system, energy storage #AMP2016
8:21am November 11th 2016 via Twitter Web Client
Indira Mysorekar (Univ Washington MO) Microbes in the placenta: friends and foes #AMP2016
8:20am November 11th 2016 via Twitter Web Client
RT @GenomicPath: Summary slide of genomic medicine history from @eric_lander 's plenary at #AMP2016. #AMPlifier https://t.co/fupMlCopQD
7:49am November 11th 2016 via Twitter Web Client
Comment from CAP person: a 1.5y pilot project in CA, going from Intuitive EHR to CA Cancer Registry to look for trends. #AMP2016
Nussbaum: New methods for consent - no longer legal-ese, new mechanisms to help address these concerns #AMP2016
7:47am November 11th 2016 via Twitter Web Client
Leonard: They did have patient representation; often decisions made too conservatively. Today crowdsourcing etc. many willing #AMP2016
7:46am November 11th 2016 via Twitter Web Client
Nussbaum: con't it will take some thinking, it isn't straightforward, an important reminder about processes and ethics #AMP2016
Comment: Person from NCI, w/so much pt data, how to navigate ethical boundaries bet research and care? Nussbaum: It does blur #AMP2016
7:45am November 11th 2016 via Twitter Web Client
Leonard: Outcomes data cannot currently be captured from LIS, EHR, thus the emph on data structure #AMP2016
7:43am November 11th 2016 via Twitter Web Client
Leonard: The points 7-8: the need for structured data; physicians were 'aghast' that they would have to give up notes. #AMP2016
7:42am November 11th 2016 via Twitter Web Client
Comment: Guardian network is already starting down this path. EHR is a jungle of data w/in a hospital. To advance: focus on data #AMP2016
7:41am November 11th 2016 via Twitter Web Client
Leonard: In cancer their EHR is starting to change, needs to be broadly applied. #AMP2016
7:37am November 11th 2016 via Twitter Web Client
Q:How to get the investment into this living, breathing system? How to get info updated? Leonard: "EHRs are basically billing" #AMP2016
7:36am November 11th 2016 via Twitter Web Client
Nussbaum: We need to be all involved in this rapid learning process, in order to move this forward #AMP2016
7:34am November 11th 2016 via Twitter Web Client
Nussbaum: (Full report and summary here via IOM: https://t.co/5Qwt51fwJa ) #AMP2016
7:32am November 11th 2016 via Twitter Web Client
Nussbaum: From an artificial clinical trial environment to an integrated care system. Deliver care, ongoing assessment, modify #AMP2016
7:31am November 11th 2016 via Twitter Web Client
Nussbaum: So pts and physicians can benefit. A rapid learning system - a system for data accumulation and evaluation #AMP2016
7:30am November 11th 2016 via Twitter Web Client
Nussbaum: Rec 10: Expand interdisciplinary collaboration for integrated guidelines on appropriate use for tests for Rx #AMP2016
7:29am November 11th 2016 via Twitter Web Client
Nussbaum: Of particular relevance to #AMP2016 audience. A Nat'l Quality Forum to dev quality measure to assess unneeded repeat collection
7:28am November 11th 2016 via Twitter Web Client
Nussbaum: Rec 9: Enh specimen handling, documentation to ensure pt safety, accuracy of test results #AMP2016
7:27am November 11th 2016 via Twitter Web Client
Nussbaum: Fund dev or eval of biomarkers to ID and overcome these barriers. Perform demo projects w/ variety of incentives #AMP2016
7:26am November 11th 2016 via Twitter Web Client
Nussbaum: Rec 8:Promote equity in access to biomarker tests; expertise for effective use. Social, economic, geographic obstacles #AMP2016
7:25am November 11th 2016 via Twitter Web Client
Nussbaum: Need description of test, results, interpretation, Rx decisions, outcomes, longitudinal data, pt-reported outcomes #AMP2016
7:23am November 11th 2016 via Twitter Web Client
Leonard: FDA, CMS, NIH, PCORI, D of VA, DoD, other partners. DB to include prospective, integrated, structured data #AMP2016
7:22am November 11th 2016 via Twitter Web Client
Bob Nussbaum (In Vitae, CA) continuing: Rec 7: nat'l DB - HHS should charge FDA, NIH to form a Task Force to create it #AMP2016
7:21am November 11th 2016 via Twitter Web Client
Leonard: As physicians learn, they can get credit for usage of decision support. #AMP2016
7:20am November 11th 2016 via Twitter Web Client
Leonard: Patient portals linked to EHRs should provide biomarker resutls in a pt-friendly manner. W/decision support, CME, CEU, MOC #AMP2016
Leonard: Data structured in such a way to capture data in a national DB. Also enable HER to facilitate POC decision support #AMP2016
7:18am November 11th 2016 via Twitter Web Client
Leonard: Rec 6:EHR and other LIS enables capture/linkage of biomarker tests, targeted Rx, longitudinal data in EHR #AMP2016
7:17am November 11th 2016 via Twitter Web Client
Leonard: CMS should clarify, expand implement of coverage w/evidence for additional coverage. PCORI and NIH also #AMP2016
7:16am November 11th 2016 via Twitter Web Client
Leonard: Rec 5: Ensure ongoing assessment of clin utility. Reimbursement model should support ongoing collection of data #AMP2016
7:15am November 11th 2016 via Twitter Web Client
Leonard: Current CLIA inadequate; 'don't shoot the messenger' here. #AMP2016
7:14am November 11th 2016 via Twitter Web Client
Leonard: Rec 4:Update and strengthen oversight and accreditation. HHS should 'est and enforce up-to-date lab accreditation stds' #AMP2016
7:13am November 11th 2016 via Twitter Web Client
Leonard: Rec 3: enhance communication to pts for label. Gives example of CFTR G551D 'Test Facts' mock-up, user-friendly #AMP2016
Leonard: Evidence collected over time; incentives for data repository; adjustments made over time to benefit pts #AMP2016
7:11am November 11th 2016 via Twitter Web Client
Leonard: A pathway for coordination - whether IVD, LDT or other NGS or other technology. Evidence for CDx together or indep #AMP2016
7:10am November 11th 2016 via Twitter Web Client
Leonard: Rec 2: New HHS new integrated federal review process involving FDA and CMS. Coordinate reg, coverage, reimb #AMP2016
7:09am November 11th 2016 via Twitter Web Client
Leonard: Rec 1: HHS Sec should facilitate dev of common clinical util evidentiary stds. Get variety of stakeholders (long list) #AMP2016
7:08am November 11th 2016 via Twitter Web Client
Leonard: Shows graphic w/Patients in the center: supportive policy, supporting data infrastructure, processes to improve care #AMP2016
7:06am November 11th 2016 via Twitter Web Client
Leonard: Themes: accurate, reliable and clin useful are key. Substation 'variation in the evidence used to inform reg, reimb. #AMP2016
Leonard: Pharma, academics, industry in this study. Goal: Examine policy for targeting Rx. Not all biomarker or IVDs, but targeted #AMP2016
7:04am November 11th 2016 via Twitter Web Client
Debra Leonard (Univ VT) Biomarker Tests for Molecularly Targeted Rx: Key to Unlocking Precision Medicine, an IOM Report #AMP2016
7:03am November 11th 2016 via Twitter Web Client
Join me in supporting National Capital Area Council Boy Scouts of America @AmazonSmile. #YouShopAmazonGives https://t.co/hFKoPy922V
8:01am November 6th 2016 via Twitter Web Client
Reference Materials for Your Unique Reproducibility Needs | Genomic Precision Blog @Seracare https://t.co/0V0LwseG56
3:01pm October 12th 2016 via Twitter Web Client
RT @jsoriamd: #MAPonco16 Larkin: the cancer immunogram https://t.co/BIcRzVJXvE
11:07am September 24th 2016 via Twitter Web Client
RT @jsoriamd: #MAPonco16 Larkin a history of melanoma therapy https://t.co/sCWycl1XcR
10:42am September 24th 2016 via Twitter Web Client
RT @jsoriamd: #MAPonco16 Larkin PDL1 >5% nivo as good as ipi-nivo in melanoma #immunotherapy #PrecisionMedicine https://t.co/MLyULuge71
